I am expecting positive results from DCVax-L as well. But still, timing is important. I'll give an example:
What if the German program generates positive cash flow, but the company as a whole is still burning through cash due to expanding its 2 trials. And what if the earliest phase III data won't be out until 2016.
I'm not predicting that. I'm not predicting anything. I'm waiting for more news. But that scenario is possible. And if that's what plays out, there is going to be a lot more frustration and selling because there will be a lot more dilution ahead before anything is approved.
It's going to take years and millions of dollars to get Direct approved. People here weren't predicting that before the PR. Some people here were expecting 80%-100% cures from Direct as was seen in the preclinical. Those that thought that were way off.
A lot of people have now concluded that the only possible outcome for DCVax-L is that it's working so well that it will get to market early. I hope that is correct, both for the patients and for the investors. But there are other plausible explanations for the delay in getting an update.
News 
Market Data 
Discover 
AI
